Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNO-1016 dose-ranging study in acute rhinosinusitis
2008-002794-13Phase 2Completed
- Sponsor
- Bionorica
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Sinupret in acute rhinosinusitis (ARS) (3 arms), sponsored by Bionorica. Primary endpoints: Major symptom score over 15 days and Investigator morning assessment of 5 main rhinosinusitis symptoms. Started Dec 2008; status: completed.
02
Drugs
Sinupret
03
Conditions
acute rhinosinusitis (ARS)
Beyond the preview
Go deeper on 2008-002794-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002794-13.